HomeFull speed ahead. Keep track of advancements in every frontier

TheTechno Optimist.

Hepatocyte epigenetic reprogrammingNewLimit—Hepatocyte epigenetic reprogrammingNewLimit—Hepatocyte epigenetic reprogrammingNewLimit—Hepatocyte epigenetic reprogrammingNewLimit—T cell rejuvenationNewLimit—

NewLimit

Reprogramming, liver, AI screening

US$3.1B privateest. 2021newlimit.com (opens newlimit.com)Checked 25 Sep

The brief

Analyst view
  • Raised $435M led by Founders Fund at a $3.1B valuation in Jun 2026, about triple its 2025 value.
  • Says its prototype made old human liver cells look younger on four measures, after testing over 3,000 gene-switch combinations.
  • Plans a first human trial of its liver treatment; timing is a company target.

Technical approach

As reported
Screens

Testing thousands of combos

Thousands of gene-switch combinations go into old cells at once; reading each cell's genes shows which ones turned young.

Models

Predict untested combinations

AI trained on the screens predicts which untested combos should work, so the lab tests the best bets.

Function

Test real cell function

Winners must improve real cell function, like liver cells resisting fat and alcohol damage, not just look younger.

Delivery

Temporary mRNA

mRNA in fat bubbles goes to the liver and fades on its own, a built-in limit on over-reprogramming.

Programs

NewLimit, two programs

Updated 10 Jul 2026
Hepatocyte epigenetic reprogrammingA temporary mRNA medicine carrying a set of gene switches that make old liver cells work like young ones again.ResearchNextPre-trial studies and manufacturingUpdated 10 Jul 2026View program →T cell rejuvenationSearches for gene-switch sets that make old T cells (immune fighters) multiply and work like young ones, to fight immune decline with age.ResearchNextPick lead candidateUpdated 27 Mar 2026View program →
Research · Proto · Pilot · Deploy · Scaling

Research & demos

1 item

Open technical problems

Open · Active · Partial
  • How long does it last?Open

    It's unknown how long cells stay young after the mRNA fades, or how often dosing would be needed.

  • Choosing a first indicationActive research

    Regulators need a specific liver disease to measure against, not 'liver rejuvenation'.

Upcoming catalysts

Company-wide
  • 2027First human trial of NewLimit's liver reprogramming therapy (Phase 1 in fatty liver disease)Hepatocyte epigenetic reprogrammingby ~15 mo

Peers

Cellular reprogramming · 4

Company & funding

3 rounds · as reported
Valuation
$3.1Bprivate
Raised
$610Mdisclosed private rounds
Last round
Series CJun 2026
HQ
US
Founded
2021
$100M$1B$10B202520262027$810M$3.1B

Post-money valuation, log scale

DateRoundAmountPost-moneyLead
Jun 2026Series C$435M$3.1BFounders Fund
Jul 2025Series B extension$45M——
May 2025Series B$130M$810MKleiner Perkins

Partners & customers

3 investors

People

Key people
Primer